University of Washington spinout Split Bio raised $560,000 in bridge financing to fund the manufacturing of kits that enable scientists to carry out excessive throughput single-cell RNA sequencing. The brand new cash brings Split’s whole quantity raised to $2 million, following a $1.2 million round final yr and a $225,000 award from the Nationwide Science Basis’s seed fund. Split declined to reveal its traders.
“We provide probably the most scalable single-cell platform whereas remaining the one business answer that doesn’t require the use of a customized instrument,” Split co-founder and CTO Charles Roco informed GeekWire in an electronic mail. “This funding will assist in manufacturing scale up of our Entire Transcriptome equipment whereas additionally contributing to analysis and improvement of comply with on purposes and future merchandise.”
Split was began to take benefit of a speedy improve in single-cell RNA sequencing at drug firms and inside academia. The startup’s know-how, SPLiT-seq, was developed on the UW within the lab of synthetic biology professor Georg Seelig by Roco and Alex Rosenberg, two researchers on the lab. All three are co-founders of Split Bio.
A number of massive firms promote kits for single-cell RNA sequencing, together with Illumina, Dolomite Bio and 10x Genomics, which went public final week.
Split is betting that it will possibly compete by means of scalability and ease of use. “Split Bio’s answer provides customers flexibility of their experimental design by permitting them to repair and retailer cells after pattern extraction fairly than requiring customers to proceed on to single cell barcoding. This makes it doable to gather organic samples throughout totally different days however course of all of the samples collectively utilizing a single equipment,” the corporate mentioned in a press launch.
The startup has 5 workers and is hiring for computational biologists, scientists and analysis associates.